Vanguard Group
NTRP

Vanguard Group’s Neurotrope, Inc. Common NTRP Stock Holding History

Vanguard Group’s Portfolio NTRP Stock Details NTRP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-340,548
Closed -$378K – 4238
2020
Q3 		$378K Buy
340,548
+13,889
+4% +$16K ﹤0.01% 3856
2020
Q2 		$379K Hold
326,659
– – ﹤0.01% 3831
2020
Q1 		$268K Sell
326,659
-9,635
-3% -$10.5K ﹤0.01% 3819
2019
Q4 		$330K Sell
336,294
-1,420
-0.4% -$1.11K ﹤0.01% 3871
2019
Q3 		$273K Buy
337,714
+70,979
+27% +$325K ﹤0.01% 3914
2019
Q2 		$2.14M Buy
266,735
+47,609
+22% +$320K ﹤0.01% 3454
2019
Q1 		$1.19M Buy
219,126
+4,180
+2% +$18K ﹤0.01% 3579
2018
Q4 		$767K Hold
214,946
– – ﹤0.01% 3639
2018
Q3 		$1.89M Buy
214,946
+900
+0.4% +$8.61K ﹤0.01% 3552
2018
Q2 		$2.07M Sell
214,046
-633
-0.3% -$5.83K ﹤0.01% 3489
2018
Q1 		$1.74M Buy
214,679
+350
+0.2% +$2.78K ﹤0.01% 3511
2017
Q4 		$1.51M Buy
214,329
+2,283
+1% +$13.3K ﹤0.01% 3507
2017
Q3 		$1.09M Buy
212,046
+16,917
+9% +$88.8K ﹤0.01% 3570
2017
Q2 		$1.83M Buy
+195,129
New +$2.08M ﹤0.01% 3404

Other funds holding NTRP

SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Vanguard Group's NTRP Position: Q4 2020 in Review

Vanguard Group sold out of Neurotrope, Inc. Common (NTRP) in Q4 2020, closing a stake of 340,548 shares — an estimated $378K sold.

Vanguard Group first reported a position in NTRP in Q2 2017 and held it in 14 quarters. The position peaked at $2.14M in Q2 2019. 1 fund tracked by Wall St. Rank holds NTRP as of Q4 2020.

  • Vanguard Group reported no remaining Neurotrope, Inc. Common position as of Q4 2020 after selling out during the quarter.
  • Vanguard Group sold 340,548 Neurotrope, Inc. Common shares in Q4 2020, an estimated $378K.
  • Vanguard Group first reported a position in Neurotrope, Inc. Common in Q2 2017 and held it in 14 quarters.
  • Vanguard Group's Neurotrope, Inc. Common position peaked at $2.14M in Q2 2019.
  • 1 fund tracked by Wall St. Rank held Neurotrope, Inc. Common as of Q4 2020.

Based on Vanguard Group's 13F filing for Q4 2020, filed 12 Feb 2021.